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Background: This study aimed to investigate the effect of strenuous exercise on -endorphine (-END) level 
in fibromyalgia (FM) patients compared to healthy subjects. 
Methods: We enrolled 30 FM patients and 15 healthy individuals. All study participants underwent a treadmill 
exercise test using modified Bruce protocol (M.Bruce). The goal of the test was achieving at least 70% of the 
predicted maximal heart rate (HRMax). The serum levels of -END were measured before and after the exercise 
program. Measurements were done while heart rate was at least 70% of its predicted maximum. 
Results: The mean ± the standard deviation (SD) of exercise duration in the FM and control groups were 
24.26 ± 5.29 and 29.06 ± 3.26 minutes, respectively, indicating a shorter time to achieve the goal heart rate 
in FM patients (P < 0.003). Most FM patients attained 70% HRMax at lower stages (stage 2 and 3) of M.Bruce 
compared to the control group (70% versus 6.6%, respectively; P ＜ 0.0001). Compared to healthy subjects, 
FM patients had lower serum -END levels both in baseline and post-exercise status (Mean ± SD: 122.07 
± 28.56 g/ml and 246.55 ± 29.57 g/ml in the control group versus 90.12 ± 20.91 g/ml and 179.80 ± 
28.57 g/ml in FM patients, respectively; P ＜ 0.001).
Conclusions: We found that FM patients had lower levels of -END in both basal and post-exercise status. 
Exercise increased serum the -END level in both groups but the average increase in -END in FM patients 
was significantly lower than in the control group. (Korean J Pain 2016; 29: 249-54)
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INTRODUCTION
Aerobic exercise has been increasingly known as the 
most effective intervention in FM treatment [1,2]. It stim-
ulates the secretion of endorphins/enkephalins and nora-
drenergic–serotonergic neurotransmitters [3-5] and is as-
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sociated with reduced pain perception and a higher pain 
threshold [6]. 
-END has a putative role in the attenuation of nocio-
ception signaling in ascending pain pathways [7,8]. This 
analgesic effect, however, has been observed to be de-
creased in FM [9]. According to a plausible hypothesis, no-
ciceptive signaling is more likely to gain access to the brain 
in patients with FM owing to impaired inhibitory control at 
the level of the spinal cord [9,10]. While an interest in the 
role of -END in FM surged in the mid-1980s, it soon 
waned as initial studies were unable to show any significant 
difference in serum or cerebrospinal fluid (CSF) -END 
levels between FM patients and healthy subjects [11-13]. 
However, subsequent data demonstrated high levels of en-
kephalins, another main endogenous peptide, in the CSF 
of FM patients [14]. This paradoxical observation may in-
dicate a failed attempt by central pathways to control no-
ciception in fibromyalgia [9,14].
The existing data on the endogenous opioid pain medi-
ation in FM and other chronic pain disorders has been 
mainly derived from settings where basal (resting) levels 
of endogenic opioid neuropeptides were investigated. As 
FM represents a condition of continuous distress, imposing 
a challenge to inhibitory opiate neural pathways, research 
on stress models may be more sensitive in disclosing the 
endorphin derangement in FM. 
In this study, we considered strenuous physical ex-
ercise to be analogous to a stressful condition. Since hy-
pothetically a difference between FM and healthy subjects’ 
-END levels is more probable after exercise, we raised 
this question, “How would endorphin levels change after 
exercise in FM patients and healthy subjects?” 
MATERIALS AND METHODS
This study was done at the Iranian Academic Center 
for Education, Culture and Research (ACECER). Enrolled 
FM patients aged between 18 and 60 years, and met the 
1990 American College of Rheumatology Criteria (ACR). 
Healthy participants, however, were selected from volun-
teer healthy members of the FM patients’ family. Of note, 
these healthy participants were all gender-matched and 
met age inclusion criteria.
On the other hand, we excluded patients who had used 
psychotropic drugs, opiates or hormonal replacement ther-
apy within the past 8 weeks. All subjects underwent a clin-
ical examination by one rheumatologist, and if they had 
abnormal clinical findings, cardiopulmonary disorders, 
physical impairment, or inability to exercise, they were ex-
cluded from the study as well.
All participants were asked to fill out the demographic 
characteristics form. Then, a 15-20 minute physical rest 
in supine position was offered to each person for achieving 
their basal heart rate (60 to 100 per minute). Then, a 
baseline blood sample was drawn from an anti-cubital 
vein. Another blood sample was taken at the end of the 
exercise schedule that had been arranged according to the 
modified protocol of Bruce et al. [15]. The level of exercise 
intensity was recorded in each subject when the heart rate 
reached 70% of the predicted maximal value (HRMax). 
Written informed consent was obtained from all the 
participants, and the study was approved by the Ethics 
Committee of ACECER.
1. Exercise protocol
All study participants underwent a treadmill exercise 
test using modified Bruce protocol [16]. Briefly, the protocol 
consists of 2 warm-up stages each lasting 3 minutes. The 
first is at 1.7 mph and a 0% grade, and the second is at 
1.7 mph and a 5% grade. At three minute intervals the in-
cline of the treadmill increases by 2%, and the speed in-
creases in accordance to the 10-stage protocol. The test 
is stopped when the subject cannot continue running due 
to fatigue, pain, or physical exhaustion. All subjects were 
continuously monitored for heart rate, blood pressure and 
cardiac electrical activity. When the goal of the heart rate, 
70% of the predicted heart rate maximum (HRMax), was 
achieved at any level of exercise testing, the subject was 
asked to continue the exercise for an additional 15 minutes. 
Then, after stopping exercise on the treadmill, the second 
blood sample was drawn when the heart rate was still ≥ 
70% of the HRMax.
2. Laboratory analysis
The sera were stored at −20oC until analyzed. The 
tubes containing the serum samples were number-coded 
in order to blind the laboratory personnel and the sequence 
of sample collection. Analytical measurements of serum 
-END were accomplished by high performance liquid 
chromatography (HPLC) with colorimetric detection. Briefly, 
the sample was redissolved in mobile phase and injected 
into a high performance liquid chromatography column for 
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Table 1. Intensity Level Of exercise M.Bruce Protocol in FM and








2 11 (36.7) 0 (0) 0.0001
3 10 (33.3) 1 (6.6)
4  7 (23.3) 8 (53.3)
5 1 (3.3) 4 (26.6)
6 1 (3.3) 2 (13.3)
Median (IQR) 3 (2) 4 (1)
Mean rank 17.67 33.67
M.Bruce: modified Bruce protocol, FM: fibromyalgia, HRMax: 
maximal heart rate, IQR: interquartile range.
Fig. 1. Comparison of M.Bruce stages in FM and healthy
subjects.







difference of -END P
-END level pre-exercise (g/ml) 90.12 ± 20.91 122.07 ± 28.56 31.95 < 0.001
-END level post-exercise (g/ml) 179.80 ± 28.57 246.55 ± 29.57 67.46 < 0.001
Intra-group difference of -END level (g/ml) 88.96 ± 32.8 124.48 ± 38.8 35.51 < 0.001
-END: beta endorphin, FM: fibromyalgia. *Values are mean ± SD unless indicated otherwise.  
analysis. The mobile phase contained trifluoroacetic acid 
and acetonitrile. The flow rate was 1 ml per minute through 
Vydac RPC-18 250 × 4.6 m column (Discovery Bio wide 
Pore C18 5 m [supelco]). Colorimetric detection was ac-
complished with electrochemical cells in series (schimadzu 
LC-9AUV) with a pressure of 160 psi. -END concen-
tration was then determined by comparison of the samples’ 
peak areas with the extracted standard’s peak area 
(-END humor with a molecular weight of 3462.63- 
3468.63 from Sigma-Aldrich Company, USA). Final con-
centrations were eventually calculated relative to identically 
extracted internal standard of known concentration.
3. Statistical analysis
An independent Student t-test was used to compare 
the mean of -END concentration in FM patients and in 
the control individuals. Similarly, a paired t-test was used 
to compare intra-group -END concentration means be-
fore and after the exercise. Finally, Mann-Whitney analy-
sis was performed to compare the M.Bruce stage in the 
two groups. Mean differences were considered to be stat-
istically significant when P ＜ 0.05. All statistical analyses 
were carried out using SPSS for Windows version 17.0 (IBM, 
Armonk, NY, USA).
RESULTS
All study participants were female including the 30 FM 
patients and the 15 healthy subjects. Two patients from FM 
group failed to run for the extra 15 minutes after achieving 
70% of their HRMax and left the M.Bruce protocol because 
of exhaustion.
The mean ± SD age of the FM patients was sig-
nificantly greater than that of the control group (41.7 ± 
10.26 versus 30.67 ± 4.13 years, respectively; P ＜ 
0.001). 
Mean ± SD exercise duration in the FM and in the 
control groups (including the additional 15 minutes after 
attaining 70% of HRMax) were 24.26 ± 5.29 and 29.06 
± 3.26 minutes, respectively, indicating a shorter time to 
achieve to goal heart rate in the FM patients (P ＜ 0.003). 
As illustrated in Table 1, most FM patients attained 70% 
of their HRMax at the stage 2 or 3 of the M.Bruce protocol 
(36.7% and 33.3% of total FM patients, respectively). Only 
two FM patients (6.6%) achieved 70% of their HRMax at 
higher stages (level of 5 and 6) of the M.Bruce protocol. 
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Conversely, most healthy subjects reached HRMax in 
higher stages of exercise. In fact, 93% of control subjects 
reached stage 4 (versus 30% of FM patients) and 40% (6 
persons) achieved 70% of their HRMax in stages 5 and 6 
(Fig. 1).
As shown in Table 2, FM patients had lower serum 
-END levels both in baseline and post-exercise status 
than healthy subjects. Our data also demonstrated that 
exercise increased serum -END level in both groups but 
the average rise in -END in FM patients was significantly 
lower than in the control group (Table 2).
DISCUSSION
This study revealed that FM patients had lower base-
line -END levels than healthy individuals. Moreover, a 
blunted surge response of -END to exercise was observed 
in FM patients. It was also shown that FM patients reached 
the predicted maximal heart rate in lower stages of ex-
ercise (stage 2 and 3 of modified Bruce protocol) compared 
to healthy subjects.
Initial studies examining basal serum -END levels in 
the FM population have been contradictory. For instance, 
Yunus et al. [11] and Hall et al. [12] reported that serum 
-END levels were not different between FM patient and 
healthy individuals. However, this finding was debated in 
the following studies. Panerai et al. [16] showed that mon-
onuclear cells’ -END level that probably reflects central 
-END concentrations better than plasma concentrations, 
was lower in FM patients than in healthy subjects. The re-
sults of this study are congruent with the previous data 
showing that concentration of the opioid -END is lower 
in FM patients in comparison with normal subjects. This 
lower opioid tone may be a key factor in the development 
of chronic allodynia and the increased sensitization to pe-
ripheral stimuli seen in FM patients. 
Although there were a few reports regarding the CSF 
resting level or serum level of -END in FM patients, the 
impact of stress inducers such as physical exercise on se-
rum -END had not been previously studied. In healthy 
subjects, it is known that aerobic physical activity is capa-
ble of increasing peripheral levels of -END, promoting a 
decrease in sympathetic activity, improving sleep, and fa-
cilitating psychological stability [5,17-20]. It appears that 
exercise acts upon many pain mechanisms such as the se-
rotonergic system [21], sympathetic activity [18], and 
-END [17]. Even so, in fibromyalgia patients, it seems 
that the positive results of aerobic exercise may be dimin-
ished at least partly due to failure of normal elevation of 
-END. Our data supported this hypothesis and in-
ter-group comparison of serum -END levels demon-
strated that although exercise significantly increased se-
rum -END levels in both groups, this effect was less 
prominent in the FM group. This observation might explain 
why FM patients have more post-exercise muscle pain and 
tenderness or fatigue; this fact, if confirmed, may be one 
step ahead towards understanding the mechanism of pain 
and diffuse hyperalgesia in fibromyalgia.
It has been previously shown that autonomic dysfunc-
tion may be involved in the heart rate’s variable response 
during and after exercise in FM patients [22]. Interestingly, 
we found that FM patients required lower stages of graded 
exercise to achieve the age-predicted maximal heart rate. 
We think that such exercise intolerance in these patients 
could be related to the inappropriate response of their 
heart rate to exercise and the less favorable cardio-
vascular fitness of FM patients that probably occurs in the 
context of autonomic dysfunction. Decrease in exercise 
capacity and duration in FM patients can lead to failure 
of -END and other endogenous opiates to rise normally 
after exercise. Consequently, it is conceivable that pain 
and fatigue after exercise could be impacted by autono-
mous dysfunction and lower exercise tolerance. This rela-
tionship may be further elucidated when our understanding 
of the changes in endogenous opiates during and after ex-
ercise improves.
Although physical exercise is widely acknowledged as 
a fundamental management for FM [1,2], there are very few 
studies exploring the biochemical mechanisms happening 
during exercise; therefore, the mechanisms responsible for 
the achieved benefits of exercise remain to be explained. 
This is the first study to assess the -END response 
to exercise in FM patients. Our results may guide future 
research in unifying the concepts of post-exercise symp-
toms and autonomic dysfunction seen in FM patients. Much 
interest has recently been expressed in the possible role 
of the autonomic nervous system in the pathogenesis of 
chronic pain and fatigue syndromes like FM [22]. In this 
regard, it has been suggested that abnormal sympathetic 
activation could be involved in the pathogenesis of chronic 
pain and fatigue syndromes in FM [23].
This study was limited mainly by its small sample size. 
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Furthermore, participants of both groups were not aged- 
matched. As the previous studies [24-26] showed that 
-END levels are negatively correlated with age, it means 
that the basal -END levels in our study may be influenced 
by age and the higher mean age of the FM patients might 
have contributed to the difference of basal -END levels 
between the FM group and healthy group. It is an im-
portant issue in the interpretation of our data, but it is 
worthy of special attention that -END levels rising was 
blunted after exercise in FM patients rather than control 
group. There is no study in the literature which showed the 
effect of age on post exercise -END levels. So, we postu-
lated that -END level differences between the FM group 
and healthy group are more than only “age effects”. 
Moreover, we did not evaluate the possibility that the FM 
patients had had concurrent comorbid psychiatric syn-
dromes such as depression that could have changed their 
serum -END level [24]. Also, we used peripheral values 
of -END in our study. It is important to note that the 
serum level of -END may not reflect exactly its central 
activity. In fact, the degree to which peripheral values of 
-END reflect its central activity is an ever-present chal-
lenge to clinical researchers. However, the data provide a 
compelling argument for the routine measurement of plas-
ma -END [24,27,28]. 
In summary, we found that FM patient had lower levels 
of -END in both basal and post-exercise states. It could 
be related to autonomic dysfunction, lower levels of car-
diovascular fitness or to endogenous central dysfunction. 
It remains to be explained how exercise exerts its beneficial 
effects on FM patients. In addition, it should further be 
studied whether autonomic system training by exercise 
could improve -END levels or have a positive influence 
on the other pathologic mechanisms involved in FM. These 
answers can lead to the improvement in our understanding 
of neurobiological mechanisms in FM.
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